Tactile Systems Technology, Inc. (TCMD)
Chart Events
Performance Outlook
| Previous Close | 10.32 |
| Open | 10.12 |
| Bid | 9.96 x 800 |
| Ask | 10.05 x 900 |
| Day's Range | 9.93 - 10.36 |
| 52 Week Range | 9.93 - 57.64 |
| Volume | |
| Avg. Volume | 212,598 |
| Market Cap | 199.393M |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.27 |
| Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TCMD
Related Research
- Tactile Systems Technology, IncTCMD: Lowering target price to $12.00TACTILE SYSTEMS TECHNOLOGY I has an Investment Rating of HOLD; a target price of $12.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat8 days agoArgus Research
- Zacks
Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of -35.48% and 6.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Tactile Systems Technology, Inc. Reports First Quarter 2022 Financial Results; Reaffirms Full Year 2022 Outlook
First Quarter Revenue Increased 12% Year-Over-YearMINNEAPOLIS, May 02, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today reported financial results for the first quarter ended March 31, 2022. First Quarter 2022 Summary: Total revenue increased 12% year-over-year to $48.0 million, compared to $42.8 million in
- PR Newswire
Avation Medical Announces Appointment of Chief Marketing Officer to Executive Leadership Team
Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced the appointment of Darren Wennen as its Chief Marketing Officer. He will be responsible for all aspects of marketing, sales operations and customer care as the Company prepares to bring its novel wearable therapy and digital support system to market.
